AstraZeneca's Lung, Breast Cancer Drugs Markedly Slow Disease [BNN Bloomberg (Canada)]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: BNN Bloomberg
The positive data — which will be presented Sunday at the American Society of Clinical Oncology — puts the British pharmaceutical company on course to ramp up sales of Tagrisso and Enhertu even further. Tagrisso is already Astra's top-selling cancer drug, while Enhertu's sales are climbing quickly. The results are a boost for Chief Executive Officer Pascal Soriot, who last month set an ambitious target of almost doubling sales to $80 billion by the end of the decade. Much of that growth will come from its cancer drugs, an area where Astra has invested heavily. The company plans to launch 20 new medicines by 2030, as Soriot looks to cement his legacy after 12 years in charge. One of the trials looked at Tagrisso as a maintenance therapy for patients with non-small cell lung cancer and a specific genetic mutation, who had already undergone chemoradiation. Patients taking Tagrisso saw their disease progress after a median of 39.1 months, compared to 5.6 months for those who didn't t
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial [Yahoo! Finance]Yahoo! Finance
- Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 TrialBusiness Wire
- NHS England to offer Daiichi Sankyo's quizartinib for AML [Yahoo! Finance]Yahoo! Finance
- Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance [Seeking Alpha]Seeking Alpha
- Daiichi Sankyo and MSD's ADC improves progression-free survival in NSCLC trial [Yahoo! Finance]Yahoo! Finance